Shift Biosciences, a Cambridge, UK-based biotech company using generative AI models for aging processes, raised $16M in Seed funding.
The round, which brought the total amount to $18M, was led by BGF, with participation from existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner.
The company intends to use the funds for the continued development of its artificial intelligence (AI) cell simulation platform, for the identification of genes that can safely rejuvenate cells to combat the effects of age-related illnesses.
Led by CEO Dr Daniel Ives, Shift Bioscience is building a cell simulation platform that combines generative AI with its biological aging clock, to predict which sets of genes are most likely to safely rejuvenate specific cells and then test, improve and validate these predictions.
Preliminary results from the platform were well received at the 2024 Gordon Research Conference on Systems Aging.
FinSMEs
15/10/2024